Imunon, Inc. announced Dr. Corinne Le Goff, Pharm.D. has resigned as Chief Executive Officer to pursue another business opportunity. Dr. Le Goff?s resignation will be effective as of March 15, 2024. Michael H. Tardugno, the Company?s Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, will assume day-to-day leadership until a successor is named and will continue in his role directing Company strategy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | 0.00% | +23.08% | +111.76% |
Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+111.76% | 13.54M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IMNN Stock
- News Imunon, Inc.
- Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024